Symbol not found

:CMIIU   00:00AM GMT
0.00
0.00 (0.00%)
Equity Financing / Related, Initial Public Offerings

Somalogic, Leading Ai-Data Driven Proteomics Platform For Advanced Research And Clinical Applications, To Combine With Cm Life Sciences Ii, To Drive Growth And Expand Technology Platform

Published: 03/29/2021 11:29 GMT
(CMIIU) - Somalogic, Leading Ai-data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine With Cm Life Sciences Ii, to Drive Growth and Expand Technology Platform.
Cm Life Sciences Ii Inc - Upon Closing of Deal Co Will Be Renamed & Common Stock Will Be Listed on Nasdaq Global Market Under Ticker Symbol “slgc”.
Cm Life Sciences Ii Inc - Transaction Values Somalogic at a Pre-transaction Enterprise Value of About $1.23 Billion.
Cm Life Sciences Ii Inc - Combination is Expected to Provide Up to $651 Million in Cash Proceeds for Somalogic.
Cm Life Sciences Ii Inc - Financing Includes a Fully Committed Pipe of $375 Million From Both New Investors in Somalogic and Prior Investors.
Cm Life Sciences Ii Inc - Somalogic Board at Closing Anticipated to Include New Directors Kevin Conroy, Chairman & CEO of Exact Sciences, Troy Cox.
Cm Life Sciences Ii Inc - Pipe Investors Include Funds Advised by Casdin Capital, Corvex Management, Janus Henderson Investors, Sb Management.
Cm Life Sciences Ii Inc - Combined Co Will Continue to Operate Under Somalogic Management Team.